Immune Responses to Synthetic Peptide Vaccines of Veterinary Importance

1988 ◽  
pp. 141-151 ◽  
Author(s):  
P. Frenchick ◽  
M. I. Sabara ◽  
M. K. Ijaz ◽  
L. A. Babiuk
Keyword(s):  
Immune Responses ◽  
Synthetic Peptide ◽  
Peptide Vaccines ◽  
Veterinary Importance

scholarly journals Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 417
Author(s):  
Yanqi Chan ◽  
Seyed Davoud Jazayeri ◽  
Babu Ramanathan ◽  
Chit Laa Poh
Keyword(s):  
Immune Responses ◽  
Synthetic Peptide ◽  
Neutralizing Antibodies ◽  
Peptide Vaccine ◽  
Cell Epitope ◽  
Cd8 T Cell ◽  
Peptide Vaccines ◽  
T Helper ◽  
Polystyrene Nanoparticles ◽  
Helper Epitope

Vaccination remains the major approach to the prevention of dengue. Since the only licensed live attenuated vaccine (LAV) lacked efficacy against all four serotypes, other vaccine platforms, such as synthetic peptide vaccines, should be explored. In this study, four multi-epitope peptides (P1–P4) were designed by linking a universal T-helper epitope (PADRE or TpD) to the highly conserved CD8 T cell epitope and B cell epitope (B1 or B2) against all four DENV serotypes. The multi-epitope peptides were conjugated to polystyrene nanoparticles (PSNPs) and four nanovaccines (NP1–NP4) were constructed. Mice immunized with NP1–NP4 elicited significantly higher titers of IgG and neutralizing antibodies when compared to immunization with naked P1–P4. The immune responses in mice immunized with peptide vaccines were compared with nanovaccines using ELISA, ELISPOT, and a neutralization test based on FRNT50. Among the four conjugated peptide nanovaccines, NP3 comprising the TpD T-helper epitope linked to the highly conserved B1 epitope derived from the E protein was able to elicit significant levels of IFN-γ and neutralizing antibodies to all four dengue serotypes. NP3 is a promising tetravalent synthetic peptide vaccine, but the selection of a more effective CD8+ T cell epitope and adjuvants to further improve the immunogenicity is warranted.

Application of murine T-T hybridoma cells to in vitro potency assay of human synthetic peptide vaccines

Vaccine ◽  
1996 ◽  
Vol 14 (14) ◽  
pp. 1313-1321
Author(s):  
Sheue Ching T. Yu ◽  
Bishwajit Nag
Keyword(s):  
Synthetic Peptide ◽  
Hybridoma Cells ◽  
Peptide Vaccines ◽  
Potency Assay

scholarly journals Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection

2017 ◽  
Vol 13 (8) ◽  
pp. 2463-2474 ◽  
Author(s):  
Kai Schulze ◽  
Thomas Ebensen ◽  
Saranya Chandrudu ◽  
Mariusz Skwarczynski ◽  
Istvan Toth ◽  
...  
Keyword(s):  
Immune Responses ◽  
Streptococcus Pyogenes ◽  
Peptide Vaccines ◽  
Carrier System

Hepatitis B Surface Antigen Polypeptide and Synthetic Peptide Vaccines

Hepatitis B ◽  
1984 ◽  
pp. 215-224 ◽  
Author(s):  
G. R. Dreesman ◽  
I. Ionescu-Matiu ◽  
Y. Sanchez ◽  
R. C. Kennedy ◽  
J. T. Sparrow ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Synthetic Peptide ◽  
Hepatitis B Surface Antigen ◽  
Peptide Vaccines

scholarly journals Synthetic peptide vaccines

2011 ◽  
Vol 57 (1) ◽  
pp. 14-30 ◽  
Author(s):  
A.A. Moysa ◽  
E.F. Kolesanova
Keyword(s):  
Synthetic Peptide ◽  
High Throughput Screening ◽  
Large Scale ◽  
Peptide Vaccine ◽  
Foot And Mouth Disease ◽  
Transgenic Animals ◽  
Screening Methods ◽  
Peptide Vaccines ◽  
Human Infections ◽  
Selection Of

This review considers the stages of the development of synthetic peptide vaccines against infectious agents, novel approaches and technologies employed in this process, including bioinformatics, genomics, proteomics, large-scale peptide synthesis, high-throughput screening methods, the use of transgenic animals for modelling human infections. An important role for the development and selection of efficient adjuvants for peptide immunogens is noted. Examples of synthetic peptide vaccine developments against three infectious diseases (malaria, hepatitis C, and foot-and-mouth disease) are given.

Synthetic Peptide Vaccines: Success at Last

Vaccines ◽  
1995 ◽  
pp. 127-133 ◽  
Author(s):  
R. H. Meloen ◽  
J. I. Casal ◽  
K. Dalsgaard ◽  
J. P. M. Langeveld
Keyword(s):  
Synthetic Peptide ◽  
Peptide Vaccines

scholarly journals The peptide vaccine of the future

2020 ◽  
pp. mcp.R120.002309
Author(s):  
Annika Nelde ◽  
Hans Georg Rammensee ◽  
Juliane Sarah Walz
Keyword(s):  
Immune Responses ◽  
Target Selection ◽  
Peptide Vaccine ◽  
Predictive Biomarkers ◽  
Peptide Vaccines ◽  
Peptide Vaccination ◽  
Anti Cancer ◽  
The Future ◽  
Clinical Responses ◽  
Review Current

The approach of peptide-based anti-cancer vaccination has proven the ability to induce cancer-specific immune responses in multiple studies for various cancer entities. However, clinical responses remain so far limited to single patients and broad clinical applicability was not achieved. Therefore, further efforts are required to improve peptide vaccination in order to integrate this low side effect therapy into the clinical routine of cancer therapy. To design clinically effective peptide vaccines in the future, different issues have to be addressed and optimized comprising antigen target selection as well as choice of optimal adjuvants and vaccination schedules. Furthermore, the combination of peptide-based vaccines with other immuno- and molecular targeted therapies as well as the development of predictive biomarkers could further improve efficacy. In this review, current approaches in the development of peptide-based vaccines and critical implications for optimal vaccine design are discussed.

Design and development of synthetic peptide vaccines: past, present and future

2007 ◽  
Vol 6 (4) ◽  
pp. 591-603 ◽  
Author(s):  
Martijn S Bijker ◽  
Cornelis JM Melief ◽  
Rienk Offringa ◽  
Sjoerd H van der Burg
Keyword(s):  
Synthetic Peptide ◽  
Peptide Vaccines ◽  
Design And Development
Sign in / Sign up

Export Citation Format

Share Document